Clinical Trial

A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

Study acronym: BeeHive
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The BeeHive study is an investigator-initiated, single center, open-label phase II clinical trial that is designed to conduct a comprehensive multiomic biomarker evaluation across two single-arm cohorts to elucidate mechanisms of response and resistance in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). It is anticipated that about 20 patients will be enrolled in Cohort A and an additional of 10 patients will be enrolled in Cohort B.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-04-30
minor Completion pushed: 2030-06-30 -> 2031-03-01 2026-04-30
Trial Details
NCT Number NCT07408063
Lead Sponsor University Health Network, Toronto
Collaborators: GlaxoSmithKline
Conditions Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment 30 participants
Start Date 2026-04-27
Primary Completion 2030-06-30 (estimated)
Study Completion 2031-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-29